These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 29718020)
41. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. Grant A; Gonzalez T; Montgomery MO; Cardenas V; Kerdel FA J Am Acad Dermatol; 2010 Feb; 62(2):205-17. PubMed ID: 20115947 [TBL] [Abstract][Full Text] [Related]
42. Hidradenitis suppurativa: the "bright side" of autoinflammation and hidden diseases. Marzano AV; Genovese G; Calzavara-Pinton P G Ital Dermatol Venereol; 2018 Jun; 153(3 Suppl 2):1-2. PubMed ID: 30468373 [No Abstract] [Full Text] [Related]
43. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Sotiriou E; Apalla Z; Vakirlis E; Ioannides D Eur J Dermatol; 2009; 19(2):180-1. PubMed ID: 19153066 [No Abstract] [Full Text] [Related]
44. Mooren's-type ulceration associated with severe hidradenitis suppurativa: a case report and literature review. Meskin SW; Carlson EM Ocul Immunol Inflamm; 2011 Oct; 19(5):340-2. PubMed ID: 21823931 [TBL] [Abstract][Full Text] [Related]
45. Polyclonal gammopathy in an adolescent affected by Dent disease 2 and hidradenitis suppurativa. Marzuillo P; Caiazzo R; Coppola C; Camponesco O; Miraglia Del Giudice E; Argenziano G; Manna A; Piccolo V; Guarino S Int J Dermatol; 2020 Jun; 59(6):e201-e203. PubMed ID: 31971248 [No Abstract] [Full Text] [Related]
46. High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa. Scholl L; Hessam S; Garcovich S; Bechara FG Eur J Dermatol; 2019 Dec; 29(6):659-661. PubMed ID: 31903963 [No Abstract] [Full Text] [Related]
47. Infliximab for the treatment of hidradenitis suppurativa. Fernández-Vozmediano JM; Armario-Hita JC Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838 [TBL] [Abstract][Full Text] [Related]
54. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. Gulliver WP; Jemec GB; Baker KA J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174 [TBL] [Abstract][Full Text] [Related]
55. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188 [TBL] [Abstract][Full Text] [Related]
56. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa. Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722 [TBL] [Abstract][Full Text] [Related]
57. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). Hessam S; Sand M; Gambichler T; Bechara FG J Am Acad Dermatol; 2015 Dec; 73(6):998-1005. PubMed ID: 26410359 [TBL] [Abstract][Full Text] [Related]
59. Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry. Williams JC; Alhusayen R; Guilbault S; Hills NK; Ingram JR; Kudlinski MV; Lowes MA; Marzano AV; Paul M; Villumsen B; Yannuzzi CA; Naik HB Dermatology; 2023; 239(2):283-286. PubMed ID: 36566748 [No Abstract] [Full Text] [Related]
60. Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. Marasca C; Ruggiero A; Megna M; Annunziata MC; Fabbrocini G J Dermatolog Treat; 2022 Feb; 33(1):592. PubMed ID: 32403954 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]